Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)

Exclusion Criteria

• •A history of clinically significant endocrine (except T2DM), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
• •A history of myositis or complaints including diffuse myalgias, muscle tenderness, or weakness.
• •A history of cancer (malignancy) excepting adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix
• •Has clinically unstable diabetic retinopathy, neuropathy, and/or clinical evidence of gastroparesis (frequent nausea, bloating or vomiting, severe gastroesophageal reflux, early satiety)
• •A history of type 1 diabetes mellitus and/or history of ketoacidosis
• •Taking a medication for a co-morbid condition that is not permitted during the study
• •A history of significant multiple and/or severe allergies
• •Positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus
• •Had major surgery, donated or lost 1 unit of blood within 4 weeks prior to study participation
• •Participated in another investigational trial within 4 weeks prior to study participation
• •Consumes excessive amounts of alcoholic or caffeine-containing beverages
• •A regular user of illicit drugs or a history of drug or alcohol abuse within the past year